Biosimilar tenecteplase versus alteplase in acute ischemic stroke: A real world study
Annals of Indian Academy of Neurology, 2023 Background and Purpose: There is an unmet need for a more effective thrombolytic agent in acute ischemic stroke (AIS) management. Various studies and meta-analysis suggest tenecteplase (TNK) as non-inferior over alteplase (rTPA).
Ayush Mohan +11 more
doaj +1 more source
Changes In The Prices Of Reference Biotechnology Products By The Penetration Of Biosimilars Into The Turkish Pharmaceutical Market [PDF]
Value in Health, 2015 E Tuna, G. Kockaya
openalex +2 more sources
Has The Era Of Slow Growth For Prescription Drug Spending Ended? [PDF]
, 2016 In the period 2005–13 the US prescription drug market grew at an average annual pace of only 1.8 percent in real terms on an invoice price basis (that is, in constant dollars and before manufacturers’ rebates and discounts). But the growth rate increased
Aitken, M. +4 more
core +1 more source
Biosimilar Agents for Psoriasis Treatment: The Perspective of Portuguese Patients
Acta Médica Portuguesa, 2018 Introduction: Biosimilars are highly similar copies of previously approved original biologic medicines. Their introduction on the market may yield cost reduction.
Alexandra Azevedo +3 more
doaj +1 more source
Medicines under additional monitoring in the European Union [PDF]
Farmacia Hospitalaria, 2019 Objective: The objective of this study was to analyse the characteristics of medicines subject to additional monitoring. We assessed the following aspects: the criteria applied to approve a medicine as being subject to additional monitoring; the ...
Esther Salgueiro +5 more
doaj +1 more source
Biosimilar infliximab introduction into the gastro-enterology care pathway in a large acute Irish teaching hospital: a story behind the evidence [PDF]
, 2018 Background and aim: Biosimilar medicines are not considered exact replicas of originator biological medicines. As a result, prescribers can be hesitant to introduce such medicines into the clinical setting until evidence surfaces confirming their safety ...
Byrne, Stephen +5 more
core +1 more source
Pharmacy Practice, 2021 Background: Recent approvals for novel agents such as the small molecule Janus kinase inhibitors (JAKi), combined with the advent of biosimilars has widened the gamut of available therapeutic options in the treatment of rheumatoid arthritis (RA).
Denis Choquette +6 more
doaj +1 more source
Pharmaceutical patenting trends on drugs and lifestyle diseases: an analysis of Indian and global status [PDF]
, 2017 The Indian pharmaceutical sector is large and has the potential of a global leader for low-priced high-quality drugs. The new patent regulations had a strong impact on the drug industry in India.
Chakraborty, Kajal +2 more
core +1 more source
The Impact of Biosimilar Launch on Molecule Price and Pharmaceutical Expense: The Case of the Insulin Glargine in Italy [PDF]
Value in Health, 2017 A Tettamanti +2 more
openalex +2 more sources
Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. [PDF]
, 2019 PURPOSE: To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer.
Bohlius, Julia +12 more
core +3 more sources